Abstract:
본 발명은 하기 화학식 1의 4-(3-치환-프로필옥시)-퀴놀린-2-카복실산 유도체, 그 제조방법 및 NMDA 수용체 복합체에 있는 스트리키닌 (strychinine) 비감수성 글리신 결합자리에 작용하는 강력하면서 특이성을 갖는 길항제 (antagonist)로서의 용도에 관한 것이다. 본 발명의 화합물은 신경퇴행성 질환의 치료 및 예방에 유용하다. 특히, 본 발명의 화합물은 뇌졸증, 저혈당증, 국소빈혈, 심장박동정지, 외상과 같은 빈혈이나 저산소증의 결과로서 야기되는 중추신경계의 손상을 줄이는데 유용하다. 또한, 본 발명의 화합물은 간질, 알츠하이머병, 헌팅톤병 및 파킨슨씨병을 포함하는 만성 신경퇴행성 질환의 예방 및 치료에 유용하다. 또한, 본 발명의 화합물은 항경련제, 진통제, 항우울증 치료제, 항불안 치료제 및 항정신분열증 치료제로 사용된다.
Abstract:
PURPOSE: Provided are the novel NMDA receptor antagonist, 4-(3-substituted-propyloxy)-quinoline-2-carboxylic acid derivatives and the preparation method thereof. CONSTITUTION: The derivatives are represented as shown in the chemical formula 1, where A represents carbamate, amide, thiourea, sulfonylurea, acylthiourea, thiocarbamate, amidine, guanidine, imidate, thioimidate, phosphorylamide, sulfonamide, sulfonthiourea or amines and R represents alkyl (C1¯C20), aryl (C6¯C12), aralkyl, heterocycles, carbocycles (C3¯C14), fused bicyclic, hydrogen or cyano groups. The synthetic process comprises the steps of alkylating 5,7-dichlorokynurenic acid methylester with 1,3-dibromopropane; substitution of the bromine with NaN3 to make azidomine; reducing the resultant to amine compound with Pd-catalyst; converting to amide with the corresponding isocyanate, thioisocyanate or acid chloride and finally hydrolysing the ester group in the parent moiety to make the compound of formula 1. They are strong and unique antagonist acting on the coupling position of the strychnine non-susceptive glycine in the NMDA receptor complex and penetrate effectively into central nervous system. They are effective in the treatment of neurodegeneration, especially useful for the CNS damages effected by the diseases such as heart attack, low blood sugar, local anemia and heart beat halt arising from the low oxygen concentration caused by the external wounds or anemia.